EMERGENT BIOSOLUTIONS INC. Payment for Debt Extinguishment or Debt Prepayment Cost
EMERGENT BIOSOLUTIONS INC. (EBS) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $11.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. payment for debt extinguishment or debt prepayment cost for fiscal 2025 was $3.80M.
- EMERGENT BIOSOLUTIONS INC. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|
| 2026-06-30 | $11.50M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $3.80M 10-K · filed 2026-02-27 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |